Literature DB >> 11982304

Laboratory testing for suspected Lyme disease.

Jonas Bunikis1, Alan G Barbour.   

Abstract

Laboratory testing for B. burgdorferi infection is intended to substantiate a physician's clinical judgment of whether a patient has Lyme disease or not. Cultivation of B. burgdorferi from a patient's skin or blood is the gold standard for demonstration of active infection, but it is expensive and lacks clinical sensitivity. Detection of spirochetal DNA in clinical samples by PCR has better sensitivity, but PCR for B. burgdorferi has not yet been standardized for more routine diagnostic testing. Detection of antibodies to B. burgdorferi is the most practical and common approach for laboratory work-up of a case of suspected Lyme disease. Serologic assays fall short of 100% sensitivity and specificity, however, and examination of a single specimen in time does not discriminate between previous and ongoing infection. Because of a background false positivity even among healthy populations of nonendemic regions, serologic testing is recommended only when there is at least a one in five chance, in the physician's estimation, that the patient has active Lyme disease. The pretest likelihood of the disease is determined by the physician in the context of epidemiologic and clinical facts of the case. This estimate can serve to reassure patients who are at low risk of B. burgdorferi infection but are seeking a Lyme test for complaints of a more nonspecific nature. Although new subunit serologic assays based on recombinant proteins are becoming available commercially, the longstanding two-test approach, in which a positive or indeterminate result with a standardized, sensitive ELISA test is followed by verification with a more specific Western blot assay, still provides the physician with a reasonably accurate and reliable assessment of the presence of antibodies to B. burgdorferi. More recent challenges for serologic testing are seropositivity in the population as the result of immunization with the Lyme disease vaccine and the emergence of new Borrelia species that cause Lyme disease-like illnesses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11982304     DOI: 10.1016/s0025-7125(03)00089-0

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  20 in total

1.  Seronegative Lyme arthritis.

Authors:  A Holl-Wieden; S Suerbaum; H J Girschick
Journal:  Rheumatol Int       Date:  2007-04-04       Impact factor: 2.631

2.  The laboratory diagnosis of Lyme borreliosis: Guidelines from the Canadian Public Health Laboratory Network.

Authors: 
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-03       Impact factor: 2.471

3.  Evaluation of two commercial systems for automated processing, reading, and interpretation of Lyme borreliosis Western blots.

Authors:  M J Binnicker; D J Jespersen; J A Harring; L O Rollins; S C Bryant; E M Beito
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

4.  Problems in comparing test strategies for detection of anti-Borrelia antibodies.

Authors:  A H Brandenburg; A P van Dam; J Schellekens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-12       Impact factor: 3.267

5.  Function and evolution of plasmid-borne genes for pyrimidine biosynthesis in Borrelia spp.

Authors:  Jianmin Zhong; Stephane Skouloubris; Qiyuan Dai; Hannu Myllykallio; Alan G Barbour
Journal:  J Bacteriol       Date:  2006-02       Impact factor: 3.490

Review 6.  Molecular methods for diagnosis of viral encephalitis.

Authors:  Roberta L Debiasi; Kenneth L Tyler
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Appropriateness of Lyme disease serologic testing.

Authors:  Alan H Ramsey; Edward A Belongia; Po-Huang Chyou; Jeffrey P Davis
Journal:  Ann Fam Med       Date:  2004 Jul-Aug       Impact factor: 5.166

Review 8.  [Neuroborreliosis].

Authors:  R Kaiser; V Fingerle
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

9.  A genome-wide proteome array reveals a limited set of immunogens in natural infections of humans and white-footed mice with Borrelia burgdorferi.

Authors:  Alan G Barbour; Algimantas Jasinskas; Matthew A Kayala; D Huw Davies; Allen C Steere; Pierre Baldi; Philip L Felgner
Journal:  Infect Immun       Date:  2008-05-12       Impact factor: 3.441

10.  Lyme disease testing by large commercial laboratories in the United States.

Authors:  Alison F Hinckley; Neeta P Connally; James I Meek; Barbara J Johnson; Melissa M Kemperman; Katherine A Feldman; Jennifer L White; Paul S Mead
Journal:  Clin Infect Dis       Date:  2014-05-30       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.